Hui Gan

14.8k total citations · 3 hit papers
326 papers, 7.5k citations indexed

About

Hui Gan is a scholar working on Oncology, Genetics and Molecular Biology. According to data from OpenAlex, Hui Gan has authored 326 papers receiving a total of 7.5k indexed citations (citations by other indexed papers that have themselves been cited), including 116 papers in Oncology, 80 papers in Genetics and 70 papers in Molecular Biology. Recurrent topics in Hui Gan's work include Glioma Diagnosis and Treatment (78 papers), HER2/EGFR in Cancer Research (34 papers) and Cancer Immunotherapy and Biomarkers (33 papers). Hui Gan is often cited by papers focused on Glioma Diagnosis and Treatment (78 papers), HER2/EGFR in Cancer Research (34 papers) and Cancer Immunotherapy and Biomarkers (33 papers). Hui Gan collaborates with scholars based in Australia, China and United States. Hui Gan's co-authors include Andrew M. Scott, Sagun Parakh, Terrance G. Johns, Umbreen Hafeez, Rodney B. Luwor, Benoît You, Anna N. Cvrljevic, Andrew H. Kaye, Julien Péron and Taolei Sun and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and Angewandte Chemie International Edition.

In The Last Decade

Hui Gan

305 papers receiving 7.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Risk factors for severe and critically ill COVID‐19 patients: A review

2020 850 citations Yadong Gao, Mei Ding et al. Allergy profile →
Antibody–Drug Conjugates for Cancer Therapy

2020 278 citations Hui Gan, Andrew M. Scott et al. Molecules profile →
Pharmacological Effects of Astragaloside IV: A Review

2023 87 citations Zhiyun Meng, Hui Gan et al. Molecules profile →

Peers

Countries citing papers authored by Hui Gan

Since Specialization

Citations

This map shows the geographic impact of Hui Gan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hui Gan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hui Gan more than expected).

Fields of papers citing papers by Hui Gan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hui Gan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hui Gan. The network helps show where Hui Gan may publish in the future.

Co-authorship network of co-authors of Hui Gan

This figure shows the co-authorship network connecting the top 25 collaborators of Hui Gan. A scholar is included among the top collaborators of Hui Gan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hui Gan. Hui Gan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Xanthoceras sorbifolium Oil Attenuates Hyperlipidemia Through Dual Modulation of Gut Microbiota and Lipid Metabolites: Mechanistic Insights from Lipidomics and 16S rRNA Sequencing 2025 ·Metabolites ·Yuan Tao, Miaomiao Yao, (unknown), Xi Kang, Feng Shi, Xuan Hu, Zhiyun Meng, Hui Gan, (unknown), Yunbo Sun, Guifang Dou, Shuchen Liu	0
2	Patient Safety Events Among People from Ethnic Minority Backgrounds: A Retrospective Medical Record Review of Australian Cancer Services 2025 ·Journal of Racial and Ethnic Health Disparities ·Ashfaq Chauhan, (unknown), Melvin Chin, Meron Pitcher, Carlene Wilson, Elizabeth Manias, (unknown), Hui Gan, (unknown), Ramesh Walpola, Holly Seale, Ramya Walsan, Reema Harrison	1
3	Long Noncoding RNA GAS5-Involved Progression of Neonatal Hydrocephalus and Inflammatory Responses 2024 ·Molecular Biotechnology ·(unknown), Qin Zhang, Hui Gan, Yue Qin, Yudong Zhou, Xuan Zhai, (unknown)	1
4	Stereotactic Body Radiotherapy in Recurrent and Oligometastatic Head and Neck Tumours 2024 ·Journal of Clinical Medicine ·(unknown), Sweet Ping Ng, Richard Khor, Morikatsu Wada, Hui Gan, Alesha Thai, June Corry, Houda Bahig, Antti Mäkitie, Sandra Nuyts, Remco de Bree, Primož Strojan, Wai Tong Ng, Avraham Eisbruch, James Chung Hang Chow, Alfio Ferlito	2
5	Identification of epidermal growth factor receptor as an immune-related biomarker in epilepsy using multi-transcriptome data 2023 ·Translational Pediatrics ·(unknown), Xiao Han, Hui Chen, Hui Gan, Mi Zhang, (unknown), (unknown), Xuan Zhai	3
6	Cepharanthine Dry Powder Inhaler for the Treatment of Acute Lung Injury 2023 ·Molecules ·(unknown), Wanmei Wang, (unknown), Jian Li, Guifang Dou, Hui Gan, (unknown), Lina Du, (unknown)	5
7	1318MO First-in-human study of ABBV-637, an EGFR-targeting BCL-XL–inhibiting antibody-drug conjugate combined with osimertinib (OSI) in relapsed/refractory, EGFR-mutated non-small cell lung cancer (NSCLC) 2023 ·Annals of Oncology ·Julia Rotow, Saiama N. Waqar, K. Papadopoulos, J-Y. Hung, Alexander I. Spira, Hui Gan, Tatsuya Yoshida, (unknown), (unknown), Enriqueta Felip, Kiyotaka Yoh, (unknown), Randy Robinson, Nandini Rudra-Ganguly, (unknown), Byoung Chul Cho	4
8	Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours 2023 ·Nature Reviews Clinical Oncology ·Maximilian J. Mair, Rupert Bartsch, Émilie Le Rhun, Anna S. Berghoff, Priscilla K. Brastianos, Javier Cortés, Hui Gan, Nancy U. Lin, Andrew B. Lassman, Patrick Y. Wen, Michael Weller, Martin J. van den Bent, Matthias Preusser	45
9	Bromodomain and extraterminal protein-targeted probe enables tumour visualisation in vivo using positron emission tomography 2023 ·Chemical Communications ·(unknown), (unknown), Nhi Huynh, Angela Rigopoulos, Zhanqi Liu, (unknown), Laura D. Osellame, Michael A. Gorman, Michael W. Parker, Hui Gan, Andrew M. Scott, Uwe Ackermann, Ingrid J.G. Burvenich, Jonathan M. White	1
10	Evaluation of the metabolism of PEP06, an endostatin-RGDRGD 30-amino-acid polypeptide and a promising novel drug for targeting tumor cells 2022 ·Journal of Pharmaceutical Analysis ·(unknown), (unknown), (unknown), Ya Gao, Yulu Liu, (unknown), Zhuona Wu, X. X. Zhu, Hui Gan, Zhiyun Meng, Guifang Dou	2
11	EGFRvIII Promotes Cell Survival during Endoplasmic Reticulum Stress through a Reticulocalbin 1-Dependent Mechanism 2021 ·Cancers ·(unknown), (unknown), (unknown), Hong Nguyen, (unknown), (unknown), (unknown), Vijay Rajagopal, Magdalene K. Montgomery, Hui Gan, Andrew M. Scott, Jordan Jones, Andrew H. Kaye, Andrew Morokoff, Rodney B. Luwor	12
12	Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma 2021 ·Neuro-Oncology Advances ·Mustafa Khasraw, Michael Weller, David Lorente, Kathryn S. Kolibaba, Chee Khoon Lee, Craig Gedye, Macarena I. de la Fuente, David Vicente, David A. Reardon, Hui Gan, Andrew M. Scott, Isabelle Dussault, Christoph Helwig, Laureen S. Ojalvo, (unknown), Morris D. Groves	18
13	Radiolabelling and preclinical characterization of 89Zr-Df-radiolabelled bispecific anti-PD-L1/TGF-βRII fusion protein bintrafusp alfa 2021 ·European Journal of Nuclear Medicine and Molecular Imaging ·Ingrid J.G. Burvenich, (unknown), (unknown), Hui Gan, Angela Rigopoulos, Diana Cao, Zhanqi Liu, Uwe Ackermann, Christian Wichmann, (unknown), Nhi Huynh, Graeme O’Keefe, Sylvia Gong, Fiona E. Scott, Linghui Li, Wanping Geng, Anup Zutshi, Lan Yan, Andrew M. Scott	20
14	Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody–Drug Conjugate 2020 ·Molecular Cancer Therapeutics ·Mark G. Anderson, Hugh D. Falls, Michael J. Mitten, Anatol Oleksijew, Kedar S. Vaidya, Erwin R. Boghaert, Wenqing Gao, Joann P. Palma, Diana Cao, (unknown), Thomas John, Hui Gan, Andrew M. Scott, Edward B. Reilly	30
15	Spatial and quantitative mapping of glycolysis and hypoxia in glioblastoma as a predictor of radiotherapy response and sites of relapse 2020 ·European Journal of Nuclear Medicine and Molecular Imaging ·Antoine Leimgruber, Kevin Hickson, Sze Ting Lee, Hui Gan, Lawrence Cher, John Sachinidis, Graeme O’Keefe, Andrew M. Scott	19
16	Risk factors for severe and critically ill COVID‐19 patients: A review breakdown → 2020 ·Allergy ·Yadong Gao, Mei Ding, Xiang Dong, Jinjin Zhang, Ahmet Kürşat Azkur, Dilek Azkur, Hui Gan, Yuanli Sun, Wei Fu, Wei Li, Huiling Liang, Yiyuan Cao, Yan Qi, Can Cao, Hongyu Gao, Marie‐Charlotte Brüggen, Willem van de Veen, Milena Sokołowska, Mübeccel Akdiş, Cezmi A. Akdiş	850
17	First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Antitumor Activity 2019 ·Clinical Cancer Research ·Hui Gan, Michael Millward, Hua Ye, (unknown), Yang Sai, Weiguo Su, Jian Wang, (unknown), Melanie M. Frigault, Shethah Morgan, Liu Yang, Jason D. Lickliter	41
18	Comparison of Biomarker Assays for EGFR : Implications for Precision Medicine in Patients with Glioblastoma 2019 ·Clinical Cancer Research ·Andrew B. Lassman, Lisa Roberts-Rapp, И. А. Соколова, (unknown), Ekaterina Pestova, (unknown), (unknown), Zheng Zha, Xin Lü, Erica Gomez, Anahita Bhathena, David Maag, Priya Kumthekar, Hui Gan, Andrew M. Scott, (unknown), Kyle D. Holen, Peter Ansell, Martin J. van den Bent	25
19	ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled, phase 3 study of rucaparib plus nivolumab following front-line platinum-based chemotherapy in ovarian cancer 2018 ·Asia-Pacific Journal of Clinical Oncology ·Mustafa Khasraw, Kerrie L. McDonald, Sonia Yip, Roel G.W. Verhaak, Amy B. Heimberger, (unknown), Lauren Fisher, (unknown), Mark Rosenthal, Craig Gedye, Elizabeth Hovey, Benjamin M. Ellingson, John Simes, (unknown), Helen Wheeler, Eng‐Siew Koh, Hui Gan, Michael Back, Zarnie Lwin	1
20	Adherence to CONSORT Adverse Event Reporting Guidelines in Randomized Clinical Trials Evaluating Systemic Cancer Therapy: A Systematic Review 2013 ·Journal of Clinical Oncology ·Julien Péron, Denis Maillet, Hui Gan, Eric X. Chen, Benoît You	90

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact